Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

683 results about "Monilinia fructicola" patented technology

Monilinia fructicola is a species of fungus in the order Helotiales. A plant pathogen, it is the causal agent of brown rot of stone fruits.

Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories

InactiveUS20040185478A1Reduce usageDetermine rapidly the bacterial resistance to antibioticsMicrobiological testing/measurementFermentationBacteroidesNeisseria meningitidis
DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample DNA from (i) any bacterium, (ii) the species Streptococcus agalactiae, Staphylococcus saprophyticus, Enterococcus faecium, Neisseria meningitidis, Listeria monocytogenes and Candida albicans, and (iii) any species of the genera Streptococcus, Staphylococcus, Enterococcus, Neisseria and Candida are disclosed. DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample antibiotic resistance genes selected from the group consisting of blatem, blarob, blashv, blaoxa, blaZ, aadB, aacC1, aacC2, aacC3, aacA4, aac6'-lla, ermA, ermB, ermC, mecA, vanA, vanB, vanC, satA, aac(6')-aph(2''), aad(6'), vat, vga, msrA, sul and int are also disclosed. The above microbial species, genera and resistance genes are all clinically relevant and commonly encountered in a variety of clinical specimens. These DNA-based assays are rapid, accurate and can be used in clinical microbiology laboratories for routine diagnosis. These novel diagnostic tools should be useful to improve the speed and accuracy of diagnosis of microbial infections, thereby allowing more effective treatments. Diagnostic kits for (i) the universal detection and quantification of bacteria, and / or (ii) the detection, identification and quantification of the above-mentioned bacterial and fungal species and / or genera, and / or (iii) the detection, identification and quantification of the above-mentioned antibiotic resistance genes are also claimed.
Owner:GENEOHM SCI CANADA

Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories

DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample DNA from (i) any bacterium, (ii) the species Streptococcus agalactiae, Staphylococcus saprophyticus, Enterococcus faecium, Neisseria meningitidis, Listeria monocytogenes and Candida albicans, and (iii) any species of the genera Streptococcus, Staphylococcus, Enterococcus, Neisseria and Candida are disclosed. DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample antibiotic resistance genes selected from the group consisting of blatem, blarob, blashv, blaoxa, blaZ, aadB, aacC1, aacC2, aacC3, aacA4, aac6'-lla, ermA, ermB, ermC, mecA, vanA, vanB, vanC, satA, aac(6')-aph(2''), aad(6'), vat, vga, msrA, sul and int are also disclosed. The above microbial species, genera and resistance genes are all clinically relevant and commonly encountered in a variety of clinical specimens. These DNA-based assays are rapid, accurate and can be used in clinical microbiology laboratories for routine diagnosis. These novel diagnostic tools should be useful to improve the speed and accuracy of diagnosis of microbial infections, thereby allowing more effective treatments. Diagnostic kits for (i) the universal detection and quantification of bacteria, and/or (ii) the detection, identification and quantification of the above-mentioned bacterial and fungal species and/or genera, and/or (iii) the detection, identification and quantification of the above-mentioned antibiotic resistance genes are also claimed.
Owner:BERGERON MICHEL G +3

Methods and compositions for detecting and identifying species of Candida

Methods and compositions useful in the detection and identification of species of Candida are disclosed. These species include Candida albicans, Candida glabrata, Candida parapsilosis, and Candida tropicalis, each of which is a causative agent for vaginal candidiasis. The compositions of the invention are combinations of oligonucleotides. These oligonucleotides include pairs of forward and reverse primers for polymerase chain reactions, wherein each primer pair is capable of priming the synthesis of an amplicon specific to one of Candida albicans, Candida glabrata, Candida parapsilosis, and Candida tropicalis, but preferably is not capable of priming the synthesis of an amplicon specific to any of the other three species. In preferred embodiments, the forward primers of the primer pairs have identical sequences, while each reverse primer of the primer pairs has a unique sequence relative to all of the other reverse primers; or the reverse primers of the primer pairs have identical sequences, while each forward primer of the primer pairs has a unique sequence relative to all of the other forward primers. These unique primer sequences account for the species specificity of the resultant amplicons. The oligonucleotides also include probes capable of detecting these amplicons, and sequencing primers for determining, in primer extension reactions, the nucleotide sequences contained within the amplicons. In preferred methods of the invention, a biological sample is tested for the presence of at least one isolate of Candida albicans, Candida glabrata, Candida parapsilosis, and Candida tropicalis by isolating nucleic acid from the sample, attempting a polymerase chain reaction in a mixture containing this nucleic acid and a plurality of these primer pairs, ascertaining whether any amplicon is produced in the mixture using an oligonucleotide probe, and determining the sequence of any resultant amplicon using the sequencing primers. The detection of an amplicon indicates that the sample contains at least one isolate of Candida albicans, Candida glabrata, Candida parapsilosis, or Candida tropicalis, and the nucleotide sequence data is used to determine which of these four Candida species is present.
Owner:MEDICAL DIAGNOSTIC LAB

Traditional Chinese medicine antibiotic skincare hand cleanser and preparation method thereof

The invention relates to a traditional Chinese medicine antibiotic skincare hand cleanser prepared from mixed materials of a traditional Chinese medicine extract, a surfactant, an antiseptic, glycerin, an essence and water. The traditional Chinese medicine extract is prepared from raw materials of, by weight: 35-45 parts of lightyellow sophora root, 15-25 parts of amur corktree bark, 15-25 parts of Chinese gentian, 5-15 parts of common cnidium fruit, and 5-15 parts of belvedere fruit. The raw materials are extracted by using water, and the density d of the obtained traditional Chinese medicine extract is 1.5-1.8g/ml. The traditional Chinese medicine antibiotic skincare hand cleanser provided by the invention has certain inhibitive effects against escherichia coli, staphylococcus aureus, and candida albicans, and provides certain preventive effects against eczema, skin pruritus, and the like. The hand cleanser is also advantaged in small dosage, high decontamination capability, good sterilization effect, and low irritation. The hands are delicate and not dry after washing. According to the invention, the formula of the hand cleanser is simple. With the hand cleanser, modern market requirements on naturalness, environment-friendliness, and high antibiotic efficiency can be satisfied.
Owner:SHANXI ZHENDONG PHARMA

Preparation methods of sustained-release microcapsule and sustained-release composite membrane for inhibiting monilinia fructicola

The invention discloses preparation methods of a sustained-release microcapsule and a sustained-release composite membrane for inhibiting the monilinia fructicola. The preparation method of the sustained-release microcapsule comprises the following steps: the chitosan and the berberine are weighed, the mass ratio between the chitosan and the berberine is 9-11:0.22-0.28, the acetate solution is added, then the chitosan and the berberine are sufficiently swelled to obtain berberine-chitosan solution after stirring for dissolving, standing and air bubble removal, and the berberine-chitosan solution is added in the soybean oil containing span 80, stirred at the constant temperature of 40-50 DEG C and then emulsified for 28-32 min to form a W/O system; the glutaraldehyde solution is added for stirring for 2.5-3.5 hours, and the centrifuging is carried out so that the microcapsule is fully settled; and the preparation liquid on the upper layer is obliquely taken, the obtained microcapsule is washed with petroleum ether for 3-5 times and then dried for 23-25 hours under the vacuum at the temperature of 48-52 DEG C. The invention also provides the preparation method for the sustained-release composite membrane for inhibiting the monilinia fructicola. Both the microcapsule and the composite membrane have the sustained-release effects and have no toxic side effect to the environment and the plants since the berberine is a native compound.
Owner:BEIJING UNIV OF CHEM TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products